NR4A1 and prostate cancer: Our data show that docetaxel/trastuzumab combination caused a simultaneous hormone-receptor and HSP90 degradation and enhances the antitumour efficacy of docetaxel, suggesting that complete inactivation of AR could affect HID prostate cancers.